Full Press Release Details
EXTON, Pa. , July 25, 2019 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST ) today announced its financial results for the second-quarter 2019 and updated full-year 2019 financial guidance.
Second-Quarter 2019 Summary (comparisons to prior-year period)
"Adjusted-diluted EPS" and "organic sales growth" are Non-U.S. GAAP measurements. See discussion under the heading "Non-U.S. GAAP Financial Measures" in this release.
"I am pleased with the second-quarter results led by strong Proprietary Products performance, especially in our Biologics market unit," said Eric M. Green , President and Chief Executive Officer. "Double-digit organic sales growth in our high-value product portfolio fueled both overall organic sales growth as well as increases in gross and operating profit margin. We are raising our outlook for the full-year 2019 given the underlying strength in our end markets as demonstrated by our growing book of committed orders."
Proprietary Products Segment Net sales grew by 4.1% to $360.3 million . Organic sales growth was 7.5%, with currency translation decreasing sales by 3.7% and incremental sales from a recent acquisition contributing 30 basis points of Proprietary Products growth. High-value products (HVP) represented 62% of segment sales and generated double-digit organic sales growth.
Our Biologics market unit had double-digit organic sales growth, led by customer purchases of Westar ® and NovaPure ® components as well as Crystal Zenith ® and SmartDose ® technology. Our Generics market unit posted high-single digit organic sales growth, led by sales of Westar and film-coated components. Our Pharma market unit saw a low-single digit organic decline due to the impact of a previously-reported voluntary recall of our Vial2Bag ® product.
Contract-Manufactured Products Segment Net sales grew by 7.7% to $109.4 million . Organic sales growth was 10.2% with currency translation decreasing sales by 2.5%. Segment performance was led by strong sales of healthcare-related injection and diagnostic devices.
Financial Highlights (first six months of 2019) Operating cash flow was $152.7 million , an increase of 20%. Capital expenditures were $57.1 million . Free cash flow (operating cash flow minus capital expenditures) was $95.6 million , an increase of 21%.
The Company recorded $2.0 million of restructuring and related charges through the first six months of 2019 from actions we have taken that are intended to streamline our manufacturing network. This plan is expected to be completed by the end of 2019 and result in $7.0 million of restructuring and related charges in 2019. Implemented in first-quarter 2018, the Company expects cumulative expenses over the plan period to be approximately $16.0 million . Once fully completed, the Company anticipates that the plan will provide annualized savings of approximately $14.0 million .
Full-Year 2019 Financial Guidance
Second-Quarter 2019 Conference Call The Company will host a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time today. To participate on the call please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 6143018.
A live broadcast of the conference call will be available at the Company's website, www.westpharma.com , in the "Investors" section. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company's website.
An online archive of the broadcast will be available at the website three hours after the live call and will be available through Thursday, August 1, 2019 , by dialing 855-859-2056 (U.S.) or 404-537-3406 (International) and entering conference ID 6143018.
Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Non-U.S. GAAP Financial Measures For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translates the current-period reported sales of subsidiaries whose functional currency is other than the U.S. Dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to financial results excluding the effects of unallocated items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and the effects of unallocated items are not in conformity with U.S. generally accepted accounting principles (U.S. GAAP) and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position. A reconciliation of these adjusted Non-U.S. GAAP financial measures to the comparable U.S. GAAP financial measures is included in the accompanying tables.
| WEST PHARMACEUTICAL SERVICES, INC. CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) ( in millions, except per share data) | ||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||
| 2019 | 2018 | 2019 | 2018 | |||||
| Net sales | $469.7 | 100% | $447.5 | 100% | $913.2 | 100% | $863.2 | 100% |
| Cost of goods and services sold | 311.8 | 66 | 305.3 | 68 | 608.5 | 67 | 586.6 | 68 |
| Gross profit | 157.9 | 34 | 142.2 | 32 | 304.7 | 33 | 276.6 | 32 |
| Research and development | 9.6 | 2 | 10.8 | 2 | 19.4 | 2 | 20.4 | 3 |
| Selling, general and administrative expenses | 70.3 | 15 | 70.0 | 16 | 138.9 | 15 | 138.3 | 16 |
| Other (income) expense, net | (2.5) | - | 1.1 | - | (4.8) | (1) | 4.2 | - |
| Operating profit | 80.5 | 17 | 60.3 | 14 | 151.2 | 17 | 113.7 | 13 |
| Interest expense, net | 1.4 | - | 1.9 | - | 2.8 | - | 3.2 | - |
| Other nonoperating income | (0.5) | - | (1.7) | - | (1.1) | - | (3.3) | - |
| Income before income taxes | 79.6 | 17 | 60.1 | 14 | 149.5 | 17 | 113.8 | 13 |
| Income tax expense | 15.5 | 3 | 6.0 | 1 | 31.6 | 4 | 18.5 | 2 |
| Equity in net income of affiliated companies | (2.0) | - | (2.0) | - | (3.6) | - | (4.4) | - |
| Net income | $66.1 | 14% | $56.1 | 13% | $121.5 | 13% | $99.7 | 11% |
| Net income per share: | ||||||||
| Basic | $0.90 | $0.76 | $1.64 | $1.35 | ||||
| Diluted | $0.88 | $0.75 | $1.61 | $1.33 | ||||
| Average common shares outstanding | 73.7 | 73.6 | 73.9 | 73.8 | ||||
| Average shares assuming dilution | 75.1 | 75.0 | 75.3 | 75.2 |
| WEST PHARMACEUTICAL SERVICES REPORTING SEGMENT INFORMATION (UNAUDITED) (in millions) | ||||
| Three Months Ended | Six Months Ended | |||
| June 30, | June 30, | |||
| Net Sales : | 2019 | 2018 | 2019 | 2018 |
| Proprietary Products | $360.3 | $346.0 | $700.7 | $672.2 |
| Contract-Manufactured Products | 109.4 | 101.5 | 212.5 | 191.0 |
| Consolidated Total | $469.7 | $447.5 | $913.2 | $863.2 |
| Gross Profit: | ||||
| Proprietary Products | $142.2 | $128.8 | $274.5 | $250.0 |
| Contract-Manufactured Products | 15.7 | 13.4 | 30.2 | 26.6 |
| Gross Profit | $157.9 | $142.2 | $304.7 | $276.6 |
| Gross Profit Margin | 33.6% | 31.8% | 33.4% | 32.0% |
| Operating Profit (Loss): | ||||
| Proprietary Products | $88.8 | $71.7 | $165.8 | $134.5 |
| Contract-Manufactured Products | 11.4 | 9.0 | 21.9 | 18.5 |
| U.S. pension expense | - | (2.3) | - | (4.7) |
| Stock-based compensation expense | (7.2) | (6.0) | (13.4) | (9.4) |
| General corporate costs | (11.1) | (9.9) | (21.1) | (19.7) |
| Adjusted Operating Profit | $81.9 | $62.5 | $153.2 | $119.2 |
| Adjusted Operating Profit Margin | 17.4% | 14.0% | 16.8% | 13.8% |
| Restructuring and related charges | (1.4) | (2.2) | (2.0) | (5.5) |
| Reported Operating Profit | $80.5 | $60.3 | $151.2 | $113.7 |
| Reported Operating Profit Margin | 17.1% | 13.5% | 16.6% | 13.2% |
| WEST PHARMACEUTICAL SERVICES RECONCILIATION OF NON-U.S. GAAP MEASURES (UNAUDITED) Please refer to "Non-U.S. GAAP Financial Measures" for more information (in millions, except per share data) | ||||
| Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS | ||||
| Three months ended June 30, 2019 | Operating profit | Income tax expense | Net income | Diluted EPS |
| Reported (U.S. GAAP) | $80.5 | $15.5 | $66.1 | $0.88 |
| Restructuring and related charges (1) | 1.4 | 0.3 | 1.1 | 0.01 |
| Adjusted (Non-U.S. GAAP) | $81.9 | $15.8 | $67.2 | $0.89 |
| Six months ended June 30, 2019 | Operating profit | Income tax expense | Net income | Diluted EPS |
| Reported (U.S. GAAP) | $151.2 | $31.6 | $121.5 | $1.61 |
| Restructuring and related charges (1) | 2.0 | 0.5 | 1.5 | 0.02 |
| Adjusted (Non-U.S. GAAP) | $153.2 | $32.1 | $123.0 | $1.63 |
| Three months ended June 30, 2018 | Operating profit | Income tax expense | Net income | Diluted EPS |
| Reported (U.S. GAAP) | $60.3 | $6.0 | $56.1 | $0.75 |
| Restructuring and related charges (1) | 2.2 | 0.6 | 1.6 | 0.01 |
| Tax law changes (2) | - | 4.8 | (4.8) | (0.06) |
| Adjusted (Non-U.S. GAAP) | $62.5 | $11.4 | $52.9 | $0.70 |
| Six months ended June 30, 2018 | Operating profit | Income tax expense | Net income | Diluted EPS |
| Reported (U.S. GAAP) | $113.7 | $18.5 | $99.7 | $1.33 |
| Restructuring and related charges (1) | 5.5 | 1.2 | 4.3 | 0.05 |
| Tax law changes (2) | - | 4.5 | (4.5) | (0.06) |
| Adjusted (Non-U.S. GAAP) | $119.2 | $24.2 | $99.5 | $1.32 |
| (1) | During the three and six months ended June 30, 2019, the Company recorded $1.4 million and $2.0 million, respectively, in restructuring and related charges. During the three and six months ended June 30, 2018, the Company recorded $2.2 million and $5.5 million, respectively, in restructuring and related charges. The Company anticipates approximately $7.0 million of restructuring and related charges in 2019 to complete its current plan. Once fully completed, the Company expects that the plan will provide annualized savings of approximately $14.0 million. |
| (2) | During the three and six months ended June 30, 2018, the Company recorded a net tax benefit of $4.8 million and $4.5 million, respectively, for the estimated impact of the Tax Cuts and Jobs Act. |
| WEST PHARMACEUTICAL SERVICES RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) Please refer to "Non-U.S. GAAP Financial Measures" for more information (in millions, except per share data) | ||||
| Reconciliation of Net Sales to Organic Net Sales (3) | ||||
| Three months ended June 30, 2019 | Proprietary | CM | Eliminations | Total |
| Reported net sales (U.S. GAAP) | $360.3 | $109.4 | $- | $469.7 |
| Effect of acquisitions and/or divestitures | (1.0) | - | - | (1.0) |
| Effect of changes in currency translation rates | 12.7 | 2.4 | - | 15.1 |
| Organic net sales (Non-U.S. GAAP) (3) | $372.0 | $111.8 | $- | $483.8 |
| Six months ended June 30, 2019 | Proprietary | CM | Eliminations | Total |
| Reported net sales (U.S. GAAP) | $700.7 | $212.5 | $- | $913.2 |
| Effect of acquisitions and/or divestitures | (1.0) | - | - | (1.0) |
| Effect of changes in currency translation rates | 29.0 | 5.7 | - | 34.7 |
| Organic net sales (Non-U.S. GAAP) (3) | $728.7 | $218.2 | $- | $946.9 |
| WEST PHARMACEUTICAL SERVICES RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) Please refer to "Non-U.S. GAAP Financial Measures" for more information (in millions, except per share data) | |||
| Reconciliation of Reported-Diluted EPS Guidance to Adjusted-Diluted EPS Guidance | |||
| 2018 Actual | 2019 Guidance | % Change | |
| Reported-diluted EPS (U.S. GAAP) | $2.74 | $2.93 to $3.03 | 6.9% to 10.6% |
| Restructuring and related charges | 0.08 | 0.07 | |
| Argentina devaluation | 0.02 | - | |
| Tax law changes | (0.03) | - | |
| Adjusted-diluted EPS (Non-U.S. GAAP) (4) | $2.81 | $3.00 to $3.10 | 6.8% to 10.3% |
| Notes: |
| See "Full-Year 2019 Financial Guidance" and "Non-U.S. GAAP Financial Measures" in today's press release for additional information regarding adjusted-diluted EPS. |
| WEST PHARMACEUTICAL SERVICES CASH FLOW ITEMS (UNAUDITED) (in millions) | ||
| Six Months Ended June 30, | ||
| 2019 | 2018 | |
| Depreciation and amortization | $51.8 | $51.9 |
| Operating cash flow | $152.7 | $127.0 |
| Capital expenditures | $57.1 | $48.2 |
| WEST PHARMACEUTICAL SERVICES FINANCIAL CONDITION (UNAUDITED) (in millions) | ||
| As of June 30, 2019 | As of December 31, 2018 | |
| Cash and cash equivalents | $326.7 | $337.4 |
| Accounts receivable, net | $330.8 | $288.2 |
| Inventories | $232.3 | $214.5 |
| Accounts payable | $152.1 | $130.4 |
| Debt | $196.0 | $196.1 |
| Equity | $1,445.1 | $1,396.3 |
| Working capital | $631.1 | $610.7 |
Trademark Notices
Trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., in the United States and other jurisdictions, unless noted otherwise.
Daikyo Crystal Zenith ® and Daikyo CZ ® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.
SOURCE West Pharmaceutical Services, Inc.